"Pyrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterocyclic aromatic organic compounds with the chemical formula C4H4N2.
| Descriptor ID |
D011719
|
| MeSH Number(s) |
D03.383.679
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazines".
Below are MeSH descriptors whose meaning is more specific than "Pyrazines".
This graph shows the total number of publications written about "Pyrazines" by people in this website by year, and whether "Pyrazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 4 | 0 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 2 | 4 |
| 2010 | 2 | 3 | 5 |
| 2011 | 5 | 5 | 10 |
| 2012 | 5 | 2 | 7 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 3 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 2 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 1 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazines" by people in Profiles.
-
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026 Feb 24; 10(4):1023-1034.
-
Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients. Leukemia. 2025 08; 39(8):1915-1927.
-
Tetramethylpyrazine: A fermented alcohol product that mitigates alcoholic liver disease in mice. Free Radic Biol Med. 2025 08 16; 236:160-175.
-
Cocrystallization improves the tabletability of ligustrazine despite a reduction in plasticity. Int J Pharm. 2024 Apr 10; 654:123939.
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 04; 204(4):1238-1242.
-
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320.
-
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplant Cell Ther. 2023 04; 29(4):265.e1-265.e10.
-
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 06 09; 139(23):3366-3375.
-
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 01; 28(5):903-914.
-
Simultaneous improvement of physical stability, dissolution, bioavailability, and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization. Int J Pharm. 2022 Mar 25; 616:121541.